Metoclopramid Polpharma

Metoclopramide, the active ingredient in Metoclopramid Polpharma, is a dopamine D2 receptor antagonist presented as an oral dosage form for oral use. The formulation conforms to EU pharmaceutical standards and is indicated for patients requiring relief from acute or chronic gastrointestinal symptoms such as nausea, vomiting, gastroparesis and gastro‑oesophageal reflux disease.

GNH USA supplies Metoclopramid Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures reliable delivery, regulatory compliance and support for procurement teams across multiple regions.

Metoclopramide acts on the gastrointestinal and central nervous systems to control emesis and improve motility. - Nausea and vomiting: reduces the frequency and severity of episodes in postoperative, chemotherapy‑induced or other causes. - Gastroparesis: enhances gastric emptying and alleviates associated dyspeptic symptoms. - Gastro‑oesophageal reflux disease (GERD): improves lower esophageal sphincter tone and reduces reflux episodes.

Metoclopramide may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Drowsiness: mild sedation or fatigue. - Restlessness: feelings of inner tension or akathisia. - Diarrhea: loose stools or increased bowel movements. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor or dystonia. - Tardive dyskinesia: persistent involuntary movements, especially with prolonged use. - Neuroleptic malignant syndrome: life‑threatening hyperthermia and muscle breakdown.

Before initiating therapy, clinicians should consider several safety measures. - Assess renal function: dose adjustment may be needed in impaired clearance. - Monitor for extrapyramidal symptoms: especially during the first weeks of treatment. - Avoid in patients with known hypersensitivity to metoclopramide or other dopamine antagonists. - Use caution in the elderly: increased susceptibility to CNS effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metoclopramide can alter the pharmacokinetics or pharmacodynamics of several co‑administered drugs.

Major Interactions (Avoid): - Anticholinergic agents: may reduce pro‑kinetic efficacy. - MAO‑inhibitors: increased risk of hypertensive crisis. - CYP2D6 substrates (e.g., codeine, tramadol): reduced metabolism leading to heightened effects.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): additive sedation. - Drugs that prolong QT interval: potential for cardiac arrhythmias.